Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03256773 · ClinicalTrials.gov registry record
High Resolution Micro OCT Imaging
A clinical trial of Cystic Fibrosis and Covid19, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT03256773 is a study of Cystic Fibrosis and Covid19 that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 60 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03256773, a study of Cystic Fibrosis and Covid19, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn about using the imaging to make images of the lungs and nose with the long-term goal of the research leading to potential treatments and new therapies for patients with cystic fibrosis.
Conditions Studied
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-04-15 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03256773
The ClinicalTrials.gov registry entry for NCT03256773 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (66% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT03256773 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT03256773 about?
NCT03256773 is a clinical study titled "High Resolution Micro OCT Imaging". The purpose of this study is to learn about using the imaging to make images of the lungs and nose with the long-term goal of the research leading to potential treatments and new therapies for patients with cystic fibrosis.
What is the current status of trial NCT03256773?
This trial is currently active not recruiting. The enrollment target is 60 participants. The study started on 2016-04-15. Estimated completion is 2026-12-31.
What conditions does trial NCT03256773 study?
This clinical trial studies the following conditions: Cystic Fibrosis, Covid19, COPD, Sinusitis, PCD - Primary Ciliary Dyskinesia.
Who is sponsoring clinical trial NCT03256773?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03256773 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise in Child Health
RECRUITING · NA
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
RECRUITING
-
Assessing Tenapanor as a Treatment of CF-related Constipation.
RECRUITING · Phase 3
-
Genetics of Insulin and Incretins in Cystic Fibrosis
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.